Drug intelligence / Profile preview

anti-TGF-beta neutralizing antibody

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Anti-TGF-beta neutralizing antibodies are a class of monoclonal antibodies designed to bind to and inhibit the biological activity of Transforming Growth Factor-beta (TGF-beta) isoforms, primarily TGF-β1, TGF-β2, and TGF-β3. TGF-beta is a pleiotropic cytokine that plays a complex role in disease; while it can inhibit the proliferation of certain cell types, such as B cells in chronic lymphocytic leukemia (CLL), it also acts as a potent immunosuppressor in the tumor microenvironment and promotes epithelial-mesenchymal transition (EMT) and fibrosis. Neutralizing antibodies are used to block these pathological effects, potentially restoring anti-tumor immune responses and inhibiting disease progression. In research settings, these antibodies have been used to demonstrate that TGF-beta acts as an autocrine growth inhibitor in CLL, contributing to the slow progression of the malignant process. This platform is being investigated for various clinical indications, including oncology and fibrotic disorders.

Other names: anti-TGF-beta antibodyTGF-beta neutralizing antibodyTGF-beta inhibitor antibody

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB2 (Transforming growth factor beta 2)TGFB3 (Transforming growth factor beta 3)

Beyond the preview

Go deeper on anti-TGF-beta neutralizing antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-TGF-beta neutralizing antibody.

Explore the full profile